Pegtibatinase as a Treatment for Participants With Classical Homocystinuria (HCU) Receiving Standard of Care Treatment (HARMONY)
Un estudio de fase 3, de tratamiento de grupos paralelos, ciego, aleatorizado y controlado con placebo para evaluar la eficacia y seguridad de la pegtibatinasa administrada por vía subcutánea además de la atención estándar en participantes con homocistinuria clásica debido a deficiencia de cistationina beta sintasa (HARMONY)
Researchers are looking for a better way to treat people living with classical homocystinuria (HCU), a rare inherited condition. It is caused by changes in the cystathionine beta-synthase (or "CBS") gene and prevents an enzyme from working correctly in the body. This enzyme helps break down homocysteine, which is produced when the body processes methionine from protein-containing foods. This helps keep homocysteine and methionine at healthy levels. When this enzyme is not working, homocysteine and methionine build up in the blood and then spread into different tissues of the body and stop these body tissues from working normally.
People living with HCU can experience problems with their vision, bones, blood vessels, thinking, learning, and memory. Available treatments for HCU include a low-methionine diet (typically achieved by limiting protein-containing foods), a methionine-free protein supplement to help meet daily protein needs, and betaine (Cystadane®). These treatments are either not sufficient or are hard to take for many patients.
Pegtibatinase was designed by researchers to act like the CBS enzyme, which is missing or not working properly in people living with HCU. Researchers are studying whether adding pegtibatinase to standard treatment can lower homocysteine levels.
Researchers want to learn how safe and effective pegtibatinase is, how it moves through and affects the body, and how it may affect the daily lives of people with HCU.
The study plans to enroll participants from the US, Australia, Belgium, France, Germany, Ireland, Italy, Poland, Portugal, Qatar, Saudi Arabia, Spain, Turkey, and the United Kingdom. Many study visits may happen at home, depending on where you live and local regulations. Some visits may include a home nurse and telemedicine appointments with the study doctor.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
Primary Objective:
Researchers want to learn more about how pegtibatinase will affect homocysteine and methionine levels when it is injected under the skin in participants already receiving standard treatment.
Blood tests will be used to measure changes in these levels during the study.
Secondary Objectives:
Researchers also want to learn:
- Is pegtibatinase safe and tolerable (how does it make participants feel)?
- How does pegtibatinase move throughout the body?
- Does pegtibatinase produce antibodies (proteins the body makes that may stop pegtibatinase from working or cause side effects)?
- How does pegtibatinase affect daily lives of participants with HCU? Researchers will use blood tests, urine tests, physical examinations, and questionnaires to answer these questions.
Study Population and Treatments:
This is a global study will include children and adults from 12 to 65 years old. Participants in the study will take their standard of care treatment. Participants will be put into 1 of 2 groups at random (like the flip of a coin) to take either:
- pegtibatinase, or
- an injection that does not have any medicine in it (or "placebo"). These are given as injections under the skin 2 times a week for up to 24 weeks. Neither the researchers nor the participant knows which treatment they are getting until the study is complete.
Study Duration and Visits:
Participants may be in the study for up to 38 weeks, including the screening period of up to 4 weeks, a pre-treatment period of up to 6 weeks where the participants will discuss their current diet with a dietitian (a health professional specialized in nutrition), a blinded treatment period of up to 24 weeks, and a safety follow-up visit completed 4 weeks after the last dose of study medication. Participants who complete the blinded treatment period may qualify to join the ENSEMBLE study before finishing the safety follow-up visit.
Participants who meet all study requirements may have up to 58 study visits. Visits may take place at a study center, at home, or by telemedicine.
These visits can include:
- Blood and urine tests
- Physical examinations
- Questionnaires
- Injections
- Questions about how they are feeling or any problems they are having
Safety / Adverse Events:
Researchers will monitor participants for any medical problems that occur during the study. Participants will have regular laboratory tests, health checkups, and study visits to monitor their health and safety.
Benefit-risk Conclusion:
Researchers have worked to reduce risks to participants in this study. They believe the risks of taking pegtibatinase in this study are justified by the potential benefits that they think pegtibatinase may have for people with HCU.
Tipo de estudio
Inscripción (Estimado)
Fase
- Fase 3
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Travere Call Center
- Número de teléfono: 1-877-659-5518
- Correo electrónico: medinfo@travere.com
Ubicaciones de estudio
-
-
-
Hamburg, Alemania
- Aún no reclutando
- Universitätsklinikum Hamburg-Eppendorf
-
Leipzig, Alemania
- Aún no reclutando
- Universitätsklinikum Leipzig
-
Münster, Alemania
- Aún no reclutando
- Universitätsklinikum Münster
-
-
-
-
-
Riyadh, Arabia Saudita
- Reclutamiento
- King Abdullah International Medical Research Center
-
Riyadh, Arabia Saudita
- Reclutamiento
- King Faisal Specialist Hospital and Research Centre (KFSHRC) - Riyadh
-
-
-
-
-
Adelaide, Australia
- Reclutamiento
- Royal Adelaide Hospital
-
Parkville, Australia
- Reclutamiento
- Royal Children's Hospital Melbourne
-
Westmead, Australia
- Reclutamiento
- Westmead Hospital
-
-
-
-
-
Brussels, Bélgica
- Reclutamiento
- Cliniques Universitaires Saint-Luc
-
Edegem, Bélgica
- Reclutamiento
- Universitair Ziekenhuis Antwerpen (UZA)
-
-
-
-
-
Barcelona, España
- Reclutamiento
- Hospital Sant Joan de Déu
-
Madrid, España
- Aún no reclutando
- Hospital Universitario 12 de Octubre
-
Madrid, España
- Reclutamiento
- Hospital Universitario Ramón y Cajal
-
Santiago de Compostela, España
- Reclutamiento
- Complejo Hospitalario Universitario de Santiago (CHUS) - Hospital Clínico Universitario
-
Seville, España
- Reclutamiento
- Hospital Universitario Virgen del Rocío
-
-
-
-
Arizona
-
Phoenix, Arizona, Estados Unidos, 85006
- Reclutamiento
- Phoenix Children's Hospital
-
-
Connecticut
-
New Haven, Connecticut, Estados Unidos, 06519
- Reclutamiento
- Yale University School of Medicine
-
-
Georgia
-
Atlanta, Georgia, Estados Unidos, 30322
- Reclutamiento
- Emory University
-
-
Illinois
-
Chicago, Illinois, Estados Unidos, 60611
- Reclutamiento
- Ann & Robert H. Lurie Children's Hospital of Chicago
-
-
Maine
-
Portland, Maine, Estados Unidos, 04102
- Reclutamiento
- Maine Health - Maine Medical Center
-
-
Maryland
-
Chevy Chase, Maryland, Estados Unidos, 20815
- Reclutamiento
- Uncommon Cures
-
-
New York
-
New York, New York, Estados Unidos, 10029
- Reclutamiento
- The Mount Sinai Hospital
-
-
North Carolina
-
Morrisville, North Carolina, Estados Unidos, 27560
- Reclutamiento
- Science 37 - Virtual Site
-
-
Oregon
-
Portland, Oregon, Estados Unidos, 97239
- Aún no reclutando
- Oregon Health and Science University
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Estados Unidos, 19104
- Reclutamiento
- Children's Hospital of Philadelphia
-
Pittsburgh, Pennsylvania, Estados Unidos, 15224
- Reclutamiento
- University of Pittsburgh Medical Center - Children's Hospital of Pittsburgh
-
-
Texas
-
Dallas, Texas, Estados Unidos, 75390
- Reclutamiento
- University of Texas Southwestern Medical Center
-
-
Utah
-
Salt Lake City, Utah, Estados Unidos, 84113
- Reclutamiento
- Utah Health - The University of Utah Primary Children's Hospital
-
-
-
-
-
Paris, Francia
- Aún no reclutando
- Assistance Publique - Hôpitaux de Paris (AP-HP) - Hôpital Necker-Enfants Malades
-
Tours, Francia
- Aún no reclutando
- CHRU Hôpitaux de Tours - Hôpital Bretonneau
-
Vandœuvre-lès-Nancy, Francia
- Aún no reclutando
- Centre Hospitalier Régional Universitaire de Nancy (CHRU) - Hopitaux de Brabois - Hôpital d'enfants
-
-
-
-
-
Dublin, Irlanda
- Aún no reclutando
- Children's Health Ireland (CHI) at Temple Street
-
-
-
-
-
Bari, Italia
- Aún no reclutando
- Ospedale Pediatrico Giovanni XXIII
-
Genova, Italia
- Aún no reclutando
- IRCCS Istituto Giannina Gaslini
-
Milan, Italia
- Aún no reclutando
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (Policlinico di Milano)
-
Monza, Italia
- Aún no reclutando
- Fondazione IRCCS San Gerardo Dei Tintori - Ospedale San Gerardo
-
Padova, Italia
- Aún no reclutando
- Azienda Ospedaliera di Padova
-
-
-
-
-
Doha, Katar
- Reclutamiento
- Hamad General Hospital
-
Doha, Katar
- Reclutamiento
- Sidra Hospital
-
-
-
-
-
Krakow, Polonia
- Aún no reclutando
- SP ZOZ Szpital Uniwersytecki w Krakowie
-
Warsaw, Polonia
- Aún no reclutando
- Instytut Matki i Dziecka
-
Warsaw, Polonia
- Aún no reclutando
- Instytut Pomnik-Centrum Zdrowia Dziecka
-
-
-
-
-
Coimbra, Portugal
- Aún no reclutando
- Unidade Local de Saúde de Coimbra, EPE - Hospitais da Universidade de Coimbra
-
Lisbon, Portugal
- Aún no reclutando
- Unidade Local de Saúde de Santa Maria, EPE - Hospital de Santa Maria
-
Porto, Portugal
- Aún no reclutando
- Unidade Local de Saúde de São João, EPE - Hospital São João
-
-
-
-
-
Birmingham, Reino Unido
- Reclutamiento
- Birmingham Women's and Children's NHS Foundation Trust
-
Birmingham, Reino Unido
- Aún no reclutando
- University Hospitals Birmingham NHS Foundation Trust - Queen Elizabeth Hospital Birmingham
-
London, Reino Unido
- Aún no reclutando
- University College London Hospitals NHS Foundation Trust - National Hospital for Neurology and Neurosurgery
-
Salford, Reino Unido
- Aún no reclutando
- Salford Royal NHS Foundation Trust - Salford Royal Hospital
-
-
-
-
-
Ankara, Turquía (Türkiye)
- Aún no reclutando
- Gazi University Hospital
-
Bornova, Turquía (Türkiye)
- Aún no reclutando
- Ege Üniversitesi Hastanesi Bornova
-
Istanbul, Turquía (Türkiye)
- Aún no reclutando
- Istanbul University Cerrahpasa Hospital
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Must be ≥12 to ≤65 years of age, at the time of signing the informed consent
- Must have a diagnosis of classical HCU based on clinical, biochemical, and/or molecular genetic testing
- Plasma tHcy ≥80 µM at Screening visit, with allowance for up to 18 participants who may be enrolled with a Screening plasma tHcy ≥50 to <80 µM
- Participants who can become pregnant must have a negative pregnancy test before starting the study and must use a highly effective form of birth control (less than 1% risk of pregnancy per year) during the study and for at least 4 weeks after the last dose.
- Willing to maintain a generally stable diet for the duration of the study (unless changes are required based on medical/safety reasons)
- Willing to maintain generally stable intake and doses of betaine, pyridoxine, and medical food for the duration of the study (unless changes are required based on medical/safety reasons)
Exclusion Criteria:
- Diagnosis of Marfan syndrome, methylenetetrahydrofolate reductase (MTHFR) deficiency, or disorder of cobalamin metabolism
- Concurrent disease or condition (eg, history or presence of clinically significant cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurological, oncologic, or psychiatric disease) that would interfere with study participation or safety (excluding complications of HCU).
- History of major thrombotic event (eg, cerebrovascular accident, myocardial infarction, pulmonary embolism) in the previous 6 months.
- Body weight ≥160 kg.
- Use or planned use of any injectable drugs containing PEG (excluding PEG-containing vaccines)
- Any previous exposure to pegtibatinase and/or previous participation in a clinical study that included administration of pegtibatinase or pegtarviliase
- Prior severe immune reaction to a PEG-containing product
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Cuadruplicar
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Comparador de placebos: placebo
|
volume-matched saline SC BIW |
|
Experimental: pegtibatinasa
|
Pegtibatinase BIW
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change from baseline in plasma tHcy levels - Weeks 6 to 12
Periodo de tiempo: Weeks 6 - 12
|
Change between baseline and average of 6 to 12 week (6, 8, 10, and 12 week) plasma tHcy levels in participants receiving pegtibatinase vs. placebo. Baseline tHcy level defined as average of Week -3, Week -1, and Day 1 pre-dose plasma tHcy |
Weeks 6 - 12
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change from baseline in plasma tHcy levels - Weeks 16 to 24
Periodo de tiempo: Weeks 16 - 24
|
Change between baseline and average of 16 to 24 week (16, 20, and 24 week) plasma tHcy levels in participants receiving pegtibatinase vs. placebo. Baseline tHcy level defined as average of Week -3, Week -1, and Day 1 pre-dose plasma tHcy |
Weeks 16 - 24
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Director de estudio: Michael Imperiale, MD, Travere Therapeutics, Inc.
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Enfermedades Cerebrales
- Enfermedades del Sistema Nervioso Central
- Enfermedades del Sistema Nervioso
- Metabolismo, errores congénitos
- Enfermedades Genéticas Congénitas
- Enfermedades metabólicas
- Enfermedades del tejido conectivo
- Enfermedades Cerebrales Metabólicas Congénitas
- Enfermedades Cerebrales Metabólicas
- Metabolismo de aminoácidos, errores congénitos
- Hiperhomocisteinemia
- Enfermedades y anomalías congénitas, hereditarias y neonatales
- Enfermedades Nutricionales y Metabólicas
- Enfermedades de la piel y del tejido conectivo
- Homocistinuria
Otros números de identificación del estudio
- TVTX-TVT058-301
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
Requests for clinical trial data, including language stating its intended use, should be directed to datarequest@travere.com. If approved, the requested information will be provided to the requestor after signing a data access agreement. Requests can be made following completion of the study and full publication of the study data in a peer reviewed journal for up to 36 months following its publication. Travere reserves the right to decline or recommend modifications to a request if it does not comply with the data sharing policy or if it is determined that the request is made by a biased source.
Marco de tiempo para compartir IPD
Requests can be made following completion of the study and full publication of the study data in a peer reviewed journal for up to 36 months following its publication.
Criterios de acceso compartido de IPD
Requires submission and approval of intended use and a data sharing agreement.
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .